This study explores the safety and effectiveness of a protein called **Alpha-1 Antitrypsin (AAT)** in stopping a condition called Graft-Versus-Host Disease (GVHD). GVHD can occur after a **Hematopoietic Cell Transplant (HCT)**, a procedure where healthy blood-forming cells are given to someone with blood cancer. The study is double-blind, which means neither the doctors nor the participants know who gets AAT or a placebo (a fake treatment). This helps make the results fair.
To join the study, you must be 12 or older (18+ in Germany) and getting a transplant for certain blood cancers like leukemia. You cannot join if you’ve had a transplant before or if certain treatments are part of your plan.
- The study will be conducted in multiple centers and is divided into two phases.
- Participants will be randomly assigned to receive either AAT or a placebo.
- It is important to discuss potential risks and benefits with your doctor.
How understandable was the trial content above?
Hard to understand
Easy to understand